JNJ

173.56

+1.32%↑

ABBV

198.07

-0.35%↓

AZN

73.59

-1.31%↓

ABT

134.42

+1.78%↑

UNH

250.68

+2.57%↑

JNJ

173.56

+1.32%↑

ABBV

198.07

-0.35%↓

AZN

73.59

-1.31%↓

ABT

134.42

+1.78%↑

UNH

250.68

+2.57%↑

JNJ

173.56

+1.32%↑

ABBV

198.07

-0.35%↓

AZN

73.59

-1.31%↓

ABT

134.42

+1.78%↑

UNH

250.68

+2.57%↑

JNJ

173.56

+1.32%↑

ABBV

198.07

-0.35%↓

AZN

73.59

-1.31%↓

ABT

134.42

+1.78%↑

UNH

250.68

+2.57%↑

JNJ

173.56

+1.32%↑

ABBV

198.07

-0.35%↓

AZN

73.59

-1.31%↓

ABT

134.42

+1.78%↑

UNH

250.68

+2.57%↑

Search

Novartis AG

Closed

116.79 0.8

Overview

Share price change

24h

Current

Min

116.52

Max

116.9

Key metrics

By Trading Economics

Income

418M

4B

Sales

660M

14B

P/E

Sector Avg

16.809

34.393

EPS

2.42

Dividend yield

3.46

Profit margin

28.18

Employees

75,883

EBITDA

-5.8B

4.9M

Recommendations

By TipRanks

Recommendations

Neutral

12 Months Forecast

+5.92% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

3.46%

2.54%

Market Stats

By TradingEconomics

Market Cap

-11B

228B

Previous open

115.99

Previous close

116.79

Technical Score

By Trading Central

Confidence

Bearish Evidence

Novartis AG Chart

Past performance is not a reliable indicator of future results.

Related News

7 Aug 2025, 05:47 UTC

Acquisitions, Mergers, Takeovers

Novartis Makes Takeover Approach for Avidity Biosciences, FT Says, Citing Sources

17 Jul 2025, 14:26 UTC

Earnings

Novartis Launches Buyback of Up to $10 Billion, Lifts Profit Outlook -- 2nd Update

17 Jul 2025, 06:49 UTC

Earnings

Novartis Launches Buyback of Up to $10 Billion, Lifts Profit Outlook -- Update

17 Jul 2025, 05:41 UTC

Earnings

Novartis Lifts Profit Outlook After Growth in Sales, Earnings

8 Aug 2025, 11:26 UTC

Market Talk

Novartis Is Getting Closer to Midterm Targets -- Market Talk

8 Aug 2025, 11:07 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Novartis Has Room to Accelerate Dealmaking -- Market Talk

8 Aug 2025, 10:51 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Novartis's Midterm Prospects Look Better Than Roche's -- Market Talk

5 Aug 2025, 10:40 UTC

Market Talk

Roche, Novartis Face Limited Tariff Headwinds for Now -- Market Talk

17 Jul 2025, 11:36 UTC

Market Talk

Novartis CEO Urges Europe to Reform Drug-Pricing System -- Market Talk

17 Jul 2025, 11:26 UTC

Market Talk

Novartis CEO Confident on Midterm Plan to Mitigate U.S. Tariff Hit -- Market Talk

17 Jul 2025, 07:14 UTC

Market Talk

Retirement of Well-Regarded Executive a Loss for Novartis -- Market Talk

17 Jul 2025, 07:02 UTC

Market Talk
Earnings

Novartis's Results Look Impressive -- Market Talk

17 Jul 2025, 05:09 UTC

Earnings

Novartis 2Q Sales Grew 11% at Constant Currency

17 Jul 2025, 05:08 UTC

Earnings

Novartis: Kirsch Will Continue as CFO, Member of Executive Committee Until March 2026

17 Jul 2025, 05:06 UTC

Earnings

Novartis: Mehta's Appointment Is Effective March 2026

17 Jul 2025, 05:05 UTC

Earnings

Novartis: Harry Kirsch Retires After 22 Years With Company

17 Jul 2025, 05:05 UTC

Earnings

Novartis Names Mukul Mehta as CFO

17 Jul 2025, 05:04 UTC

Earnings

Analysts Saw Novartis 2Q Net Profit at $3.815B

17 Jul 2025, 05:04 UTC

Earnings

Analysts Saw Novartis 2Q Core Operating Profit at $5.75B

17 Jul 2025, 05:04 UTC

Earnings

Analysts Saw Novartis 2Q Sales at $14.17B

17 Jul 2025, 05:04 UTC

Earnings

Novartis 2Q Core Operating Profit $5.925B

17 Jul 2025, 05:04 UTC

Earnings

Novartis 2Q Oper Pft $4.86B

17 Jul 2025, 05:03 UTC

Earnings

Novartis 2Q Sales $14.05B

17 Jul 2025, 05:01 UTC

Earnings

Novartis: Buyback to Be Completed by End of 2027

17 Jul 2025, 05:01 UTC

Earnings

Novartis Starting Buyback of Up to $10B

17 Jul 2025, 05:01 UTC

Earnings

Novartis Backs 2025 Sales View

17 Jul 2025, 05:01 UTC

Earnings

Novartis Had Guided for Low Double-Digit Growth in Core Operating Profit at Constant Currency

17 Jul 2025, 05:01 UTC

Earnings

Novartis Expects 2025 Core Operating Profit to Grow by Low Teens at Constant Currency

17 Jul 2025, 05:00 UTC

Earnings

Novartis Raises 2025 Earnings View

17 Jul 2025, 05:00 UTC

Earnings

Novartis AG 2Q Adj EPS $2.42

Peer Comparison

Price change

Novartis AG Forecast

Price Target

By TipRanks

5.92% upside

12 Months Forecast

Average 122.78 USD  5.92%

High 137.561 USD

Low 108 USD

Based on 3 Wall Street analysts offering 12 month price targets forNovartis AG - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

3 ratings

0

Buy

3

Hold

0

Sell

Technical Score

By Trading Central

N/A / 112.63Support & Resistance

Short Term

Bearish Evidence

Intermediate Term

Weak Bullish Evidence

Long Term

Strong Bullish Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Novartis AG

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. The company also provides Pluvicto, lutetium Lu 177 vipivotide tetraxetan, indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer; and Lutathera, lutetium Lu 177 dotatate, a prescription medicine used to treat adults and children aged 12 years and older with gastroenteropancreatic neuroendocrine tumors. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. The company has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. It also has a research collaboration and license agreement with Schrödinger, Inc. to identify and develop various therapeutic candidates; and a strategic collaboration with Vyriad, Inc. for the discovery and development for vivo chimeric antigen receptor T-cell therapies. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.